CHROMADEX CORP (CDXC) Stock Fundamental Analysis
USA - NASDAQ:CDXC - US1710774076 - Common Stock
7.87 USD
-0.07 (-0.88%)
7.87 USD
0 (0%)
Taking everything into account, CDXC scores 6 out of 10 in our fundamental rating. CDXC was compared to 58 industry peers in the Life Sciences Tools & Services industry. CDXC has an excellent financial health rating, but there are some minor concerns on its profitability. CDXC has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CDXC was profitable.
In the past year CDXC had a positive cash flow from operations.
CDXC had negative earnings in 4 of the past 5 years.
In multiple years CDXC reported negative operating cash flow during the last 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 12.52%, CDXC belongs to the top of the industry, outperforming 90.91% of the companies in the same industry.
CDXC's Return On Equity of 18.55% is amongst the best of the industry. CDXC outperforms 90.91% of its industry peers.
With an excellent Return On Invested Capital value of 12.13%, CDXC belongs to the best of the industry, outperforming 89.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROIC | 12.13% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Profit Margin value of 8.58%, CDXC is doing good in the industry, outperforming 74.55% of the companies in the same industry.
CDXC has a Operating Margin of 7.76%. This is in the better half of the industry: CDXC outperforms 63.64% of its industry peers.
CDXC's Gross Margin of 61.84% is amongst the best of the industry. CDXC outperforms 87.27% of its industry peers.
In the last couple of years the Gross Margin of CDXC has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
2. Health
2.1 Basic Checks
CDXC has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for CDXC has been increased compared to 1 year ago.
Compared to 5 years ago, CDXC has more shares outstanding
The debt/assets ratio for CDXC has been reduced compared to a year ago.
2.2 Solvency
CDXC has an Altman-Z score of 15.46. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
CDXC's Altman-Z score of 15.46 is amongst the best of the industry. CDXC outperforms 100.00% of its industry peers.
CDXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 15.46 |
ROIC/WACC1.11
WACC10.97%
2.3 Liquidity
CDXC has a Current Ratio of 3.57. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
CDXC has a Current ratio of 3.57. This is comparable to the rest of the industry: CDXC outperforms 54.55% of its industry peers.
A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
CDXC has a Quick ratio (3.06) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 242.86% over the past year.
CDXC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.17%.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
3.2 Future
The Earnings Per Share is expected to grow by 43.55% on average over the next years. This is a very strong growth
CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 78.70, CDXC can be considered very expensive at the moment.
The rest of the industry has a similar Price/Earnings ratio as CDXC.
CDXC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.13.
A Price/Forward Earnings ratio of 66.13 indicates a quite expensive valuation of CDXC.
CDXC's Price/Forward Earnings ratio is in line with the industry average.
The average S&P500 Price/Forward Earnings ratio is at 22.35. CDXC is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 |
4.2 Price Multiples
61.82% of the companies in the same industry are more expensive than CDXC, based on the Enterprise Value to EBITDA ratio.
65.45% of the companies in the same industry are more expensive than CDXC, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 51.22 | ||
| EV/EBITDA | 66.44 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDXC does not grow enough to justify the current Price/Earnings ratio.
CDXC has a very decent profitability rating, which may justify a higher PE ratio.
CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%
5. Dividend
5.1 Amount
CDXC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.87
-0.07 (-0.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners30.29%
Inst Owner Change-0.98%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 78.7 | ||
| Fwd PE | 66.13 | ||
| P/S | 6.14 | ||
| P/FCF | 51.22 | ||
| P/OCF | 50.53 | ||
| P/B | 13.27 | ||
| P/tB | 13.38 | ||
| EV/EBITDA | 66.44 |
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.52% | ||
| ROE | 18.55% | ||
| ROCE | 15.35% | ||
| ROIC | 12.13% | ||
| ROICexc | 104.84% | ||
| ROICexgc | 111.73% | ||
| OM | 7.76% | ||
| PM (TTM) | 8.58% | ||
| GM | 61.84% | ||
| FCFM | 11.99% |
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 20.02% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 7726 | ||
| Cash Conversion | 141.79% | ||
| Profit Quality | 139.72% | ||
| Current Ratio | 3.57 | ||
| Quick Ratio | 3.06 | ||
| Altman-Z | 15.46 |
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A
CHROMADEX CORP / CDXC FAQ
What is the fundamental rating for CDXC stock?
ChartMill assigns a fundamental rating of 6 / 10 to CDXC.
What is the valuation status for CDXC stock?
ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.
Can you provide the profitability details for CHROMADEX CORP?
CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.
What are the PE and PB ratios of CHROMADEX CORP (CDXC) stock?
The Price/Earnings (PE) ratio for CHROMADEX CORP (CDXC) is 78.7 and the Price/Book (PB) ratio is 13.27.
How financially healthy is CHROMADEX CORP?
The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.